ANIX Anixa Biosciences, Inc.
-
Anixa Biosciences Beat Consensus Estimates
Wednesday, June 10, 2026 · 12:00 AM ET
Anixa Biosciences (ANIX) reported a loss of $0.07 per share on revenue of $0.00 million for the fiscal second quarter ended April 2026. The consensus estimate was a loss of $0.10 per share. The company beat consensus estimates by 30.00%.
Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($0.07)
Earnings Whisper®
—
Consensus Estimate
($0.10)
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—